9-Jan-2026
No headlines found.
CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements
ACCESS Newswire (Tue, 23-Dec 4:05 PM ET)
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
ACCESS Newswire (Thu, 11-Dec 9:00 AM ET)
ACCESS Newswire (Mon, 8-Dec 9:00 AM ET)
CASI Pharmaceuticals Announces Changes in Board Governance
ACCESS Newswire (Wed, 19-Nov 9:00 AM ET)
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
ACCESS Newswire (Fri, 14-Nov 4:05 PM ET)
CASI Pharmaceuticals Receives and Appeals Delisting Determination from NASDAQ
ACCESS Newswire (Mon, 10-Nov 4:05 PM ET)
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
ACCESS Newswire (Tue, 4-Nov 9:00 AM ET)
ACCESS Newswire (Mon, 3-Nov 9:01 AM ET)
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
Casi Pharmaceuticals - trades on the NASDAQ stock market under the symbol CASI.
As of January 9, 2026, CASI stock price climbed to $1.10 with 109,669 million shares trading.
CASI has a beta of 0.62, meaning it tends to be less sensitive to market movements. CASI has a correlation of 0.01 to the broad based SPY ETF.
CASI has a market cap of $17.04 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CASI traded as high as $8.48 and as low as $.75.
CASI has underperformed the market in the last year with a return of -61.5%, while the SPY ETF gained +19.0%. In the last 3 month period, CASI fell short of the market, returning -46.3%, while SPY returned +3.7%. However, in the most recent 2 weeks CASI has outperformed the stock market by returning +39.3%, while SPY returned +0.5%.
CASI support price is $.97 and resistance is $1.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CASI shares will trade within this expected range on the day.